Pulmonx publishes investor presentation on Zephyr endobronchial valves for severe emphysema treatment

Reuters2026/07/29 20:47

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pulmonx highlighted a USD 12 billion market opportunity for Zephyr endobronchial valves in severe emphysema.
Reported 2Q26 revenue of USD 22.8 million, including USD 14.2 million in the US, with gross margin of 78%.
Cash, cash equivalents, and marketable securities totaled USD 55.8 million as of 6/30/2026.
Noted more than 50,000 patients treated globally, supported by four randomized trials and more than 100 scientific publications.
Outlined AeriSeal as an investigational program aimed at converting some ineligible patients, with potential to expand addressable market by at least 20%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pulmonx publishes investor presentation on Zephyr endobronchial valves for severe emphysema treatment

You may also like

Crypto prices